Liposomal	B-Cellular_component
honokiol	O
inhibits	O
VEGF	O
-	O
D	O
-	O
induced	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
xenograft	B-Cancer
tumor	I-Cancer
model	O
.	O

Lymph	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
metastasis	O
of	O
tumor	B-Cancer
could	O
be	O
a	O
crucial	O
early	O
step	O
in	O
the	O
metastatic	O
process	O
.	O

Induction	O
of	O
tumor	B-Cancer
lymphangiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
D	O
may	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumor	B-Cancer
metastasis	O
to	O
regional	O
lymph	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
and	O
these	O
processes	O
can	O
be	O
inhibited	O
by	O
inactivation	O
of	O
the	O
VEGFR	O
-	O
3	O
signaling	O
pathway	O
.	O

Honokiol	O
has	O
been	O
reported	O
to	O
possess	O
potent	O
antiangiogenesis	O
and	O
antitumor	B-Cancer
properties	O
in	O
several	O
cell	B-Cell
lines	I-Cell
and	O
xenograft	B-Cancer
tumor	I-Cancer
models	O
.	O

However	O
,	O
its	O
role	O
in	O
tumor	B-Cancer
-	O
associated	O
lymphangiogenesis	O
and	O
lymphatic	B-Organ
metastasis	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
established	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
models	O
by	O
injecting	O
overexpressing	O
VEGF	O
-	O
D	O
Lewis	B-Cell
lung	I-Cell
carcinoma	I-Cell
cells	I-Cell
into	O
C57BL	O
/	O
6	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
honokiol	O
on	O
tumor	B-Cancer
-	O
associated	O
lymphangiogenesis	O
and	O
related	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
.	O

The	O
underlying	O
mechanisms	O
were	O
systematically	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
in	O
vivo	O
study	O
,	O
liposomal	B-Cellular_component
honokiol	O
significantly	O
inhibited	O
the	O
tumor	B-Cancer
-	O
associated	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
Lewis	B-Cancer
lung	I-Cancer
carcinoma	I-Cancer
model	O
.	O

A	O
remarkable	O
delay	O
of	O
tumor	B-Cancer
growth	O
and	O
prolonged	O
life	O
span	O
were	O
also	O
observed	O
.	O

In	O
in	O
vitro	O
study	O
,	O
honokiol	O
inhibited	O
VEGF	O
-	O
D	O
-	O
induced	O
survival	O
,	O
proliferation	O
and	O
tube	B-Tissue
-	I-Tissue
formation	O
of	O
both	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	I-Cell
(	O
HUVECs	B-Cell
)	O
and	O
lymphatic	B-Cell
vascular	I-Cell
endothelial	I-Cell
cells	I-Cell
(	O
HLECs	B-Cell
)	O
.	O

Western	O
blotting	O
analysis	O
showed	O
that	O
liposomal	B-Cellular_component
honokiol	O
-	O
inhibited	O
Akt	O
and	O
MAPK	O
phosphorylation	O
in	O
2	O
endothelial	B-Cell
cells	I-Cell
,	O
and	O
downregulated	O
expressions	O
of	O
VEGFR	O
-	O
2	O
of	O
human	O
vascular	B-Cell
endothelial	I-Cell
cells	I-Cell
and	O
VEGFR	O
-	O
3	O
of	O
lymphatic	B-Cell
endothelial	I-Cell
cells	I-Cell
.	O

Thus	O
,	O
we	O
identified	O
for	O
the	O
first	O
time	O
that	O
honokiol	O
provided	O
therapeutic	O
benefit	O
not	O
only	O
by	O
direct	O
effects	O
on	O
tumor	B-Cell
cells	I-Cell
and	O
antiangiogenesis	O
but	O
also	O
by	O
inhibiting	O
lymphangiogenesis	O
and	O
metastasis	O
via	O
the	O
VEGFR	O
-	O
3	O
pathway	O
.	O

The	O
present	O
findings	O
may	O
be	O
of	O
importance	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
spread	O
of	O
cancer	B-Cancer
via	O
the	O
lymphatics	B-Multi-tissue_structure
and	O
explore	O
the	O
therapeutical	O
strategy	O
of	O
honokiol	O
on	O
antilymphangiogenesis	O
and	O
antimetastasis	O
.	O

